<p class="MarginalNote"><span class="wb-invisible">Marginal note:</span><span class="HistoricalNote">2014, c. 24, s. 3</span></p><ul class="ProvisionList"><li><p class="Subsection amending"><strong><a class="sectionLabel" id="s-168"><span class="sectionLabel">168</span></a></strong> <a class="lawLabel" id="s-168ss-(1)ID0ECBA"><span class="lawlabel">(1)</span></a> Section 21.71 of the French version of the Act is replaced by the following:</p><section><div class="AmendedText" lang="fr"><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Essais cliniques ou expérimentaux</p><p class="Section"><strong>21.71</strong> Le titulaire d’une autorisation relative à un produit thérapeutique visée à l’alinéa 30(1.2)c) veille à rendre publics, selon les modalités réglementaires — de temps ou autres —, les renseignements réglementaires concernant les essais cliniques ou expérimentaux.</p></div></section></li><li><p class="Subsection amending"><a class="lawLabel" id="s-168ss-(2)ID0ECAA"><span class="lawlabel">(2)</span></a> Section 21.71 of the Act is replaced by the following:</p><section><div class="AmendedText"><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Duty to publicize clinical trial information</p><p class="Section"><strong>21.71</strong> The holder of a therapeutic product authorization referred to in paragraph 30(1.2)(c) shall ensure that prescribed information concerning the clinical trial is made public within the prescribed time and in the prescribed manner.</p></div></section></li></ul>
